138 related articles for article (PubMed ID: 36593059)
21. Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma.
Porta C; Gore ME; Rini BI; Escudier B; Hariharan S; Charles LP; Yang L; DeAnnuntis L; Motzer RJ
Eur Urol; 2016 Feb; 69(2):345-51. PubMed ID: 26215605
[TBL] [Abstract][Full Text] [Related]
22. Assessing Outcomes and Prognostic Factors for First-Line Therapy in Elderly Patients With Metastatic Renal Cell Carcinoma: Real-Life Data From a Single United Kingdom Institution.
Uccello M; Alam T; Abbas H; Nair A; Paskins J; Faust G
Clin Genitourin Cancer; 2019 Jun; 17(3):e658-e663. PubMed ID: 31000484
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib (Sutent): a novel agent for the treatment of metastatic renal cell carcinoma.
Chouhan JD; Zamarripa DE; Lai PH; Oramasionwu CU; Grabinski JL
J Oncol Pharm Pract; 2007 Mar; 13(1):5-15. PubMed ID: 17621562
[TBL] [Abstract][Full Text] [Related]
24. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy.
Grande E; Alonso-Gordoa T; Reig O; Esteban E; Castellano D; Garcia-Del-Muro X; Mendez MJ; García-Donas J; González Rodríguez M; Arranz-Arija JA; Lopez-Criado P; Molina-Cerrillo J; Mellado B; Alvarez-Fernandez C; De Velasco G; Cuéllar-Rivas MA; Rodríguez-Alonso RM; Rodríguez-Moreno JF; Suarez-Rodriguez C
ESMO Open; 2022 Apr; 7(2):100463. PubMed ID: 35405437
[TBL] [Abstract][Full Text] [Related]
25. Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol.
Mouillet G; Fritzsch J; Paget-Bailly S; Pozet A; Es-Saad I; Meurisse A; Vernerey D; Mouyabi K; Berthod D; Bonnetain F; Anota A; Thiery-Vuillemin A
Health Qual Life Outcomes; 2019 Feb; 17(1):25. PubMed ID: 30717745
[TBL] [Abstract][Full Text] [Related]
26. [First-line therapy in advanced renal cell carcinoma : A randomized, open-label phase III study evaluating the efficacy and safety of pembrolizumab (MK-3475) in combination with axitinib compared to sunitinib monotherapy as first-line treatment for locally advanced or metastatic renal cell carcinoma (mRCC) (Keynote-426) - AN 39/16 of the AUO].
Rexer H; Bedke J
Urologe A; 2017 Mar; 56(3):385-386. PubMed ID: 28246756
[No Abstract] [Full Text] [Related]
27. Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Mir MH; Changal KH; Aziz SA; Bhat GM; Lone AR
Int Urol Nephrol; 2016 Nov; 48(11):1811-1816. PubMed ID: 27448573
[TBL] [Abstract][Full Text] [Related]
28. Baseline quality of life as a prognostic survival tool in patients receiving sunitinib for metastatic renal cell carcinoma.
Cella D; Bushmakin AG; Cappelleri JC; Charbonneau C; Michaelson MD; Motzer RJ
Br J Cancer; 2012 Feb; 106(4):646-50. PubMed ID: 22240794
[TBL] [Abstract][Full Text] [Related]
29. Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Revheim ME; Winge-Main AK; Hagen G; Fjeld JG; Fosså SD; Lilleby W
Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):339-43. PubMed ID: 21134733
[TBL] [Abstract][Full Text] [Related]
30. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
32. Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study).
Rodriguez-Vida A; Bamias A; Esteban E; Saez MI; Lopez-Brea M; Castellano D; Caballero C; Gonzalez-Larriba JL; Calvo E; Macia S; Ravaud A; Bellmunt J
BJU Int; 2020 Nov; 126(5):559-567. PubMed ID: 32654362
[TBL] [Abstract][Full Text] [Related]
33. Validation of a short questionnaire to measure symptoms and functional limitations associated with hand-foot syndrome and mucositis in patients with metastatic renal cell carcinoma.
Lai JS; Beaumont JL; Diaz J; Khan S; Cella D
Cancer; 2016 Jan; 122(2):287-95. PubMed ID: 26457466
[TBL] [Abstract][Full Text] [Related]
34. [Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Siebels M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
Urologe A; 2011 Sep; 50(9):1110-7. PubMed ID: 21559917
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
[TBL] [Abstract][Full Text] [Related]
36. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
37. VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.
Beuselinck B; Karadimou A; Lambrechts D; Claes B; Wolter P; Couchy G; Berkers J; van Poppel H; Paridaens R; Schöffski P; Méjean A; Verkarre V; Lerut E; Joly F; Lebret T; Gravis G; Deplanque G; Descazeaud A; Leclercq NR; Molinié V; Patard JJ; Teghom C; Elaidi R; Zucman-Rossi J; Oudard S
Acta Oncol; 2014 Jan; 53(1):103-12. PubMed ID: 23421954
[TBL] [Abstract][Full Text] [Related]
38. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis.
Deng H; Huang Y; Hong Z; Yuan X; Cao Z; Wei Y; Zhang W
BMC Cancer; 2019 May; 19(1):489. PubMed ID: 31122210
[TBL] [Abstract][Full Text] [Related]
39. Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma.
Cella D; Davis MP; Négrier S; Figlin RA; Michaelson MD; Bushmakin AG; Cappelleri JC; Sandin R; Korytowsky B; Charbonneau C; Matczak E; Motzer RJ
Cancer; 2014 Jun; 120(12):1871-80. PubMed ID: 24634003
[TBL] [Abstract][Full Text] [Related]
40. Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.
Miyake H; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2018 Jun; 38(6):3593-3599. PubMed ID: 29848715
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
